211 related articles for article (PubMed ID: 33016928)
1. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
[TBL] [Abstract][Full Text] [Related]
2. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
3. Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma.
Loh JW; Lee JY; Lim AH; Guan P; Lim BY; Kannan B; Lee ECY; Gu NX; Ko TK; Ng CC; Lim JCT; Yeong J; Lim JQ; Ong CK; Teh BT; Chan JY
Commun Biol; 2023 Apr; 6(1):461. PubMed ID: 37106027
[TBL] [Abstract][Full Text] [Related]
4. DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas.
Weidema ME; van de Geer E; Koelsche C; Desar IME; Kemmeren P; Hillebrandt-Roeffen MHS; Ho VKY; van der Graaf WTA; Versleijen-Jonkers YMH; von Deimling A; Flucke UE;
Clin Cancer Res; 2020 Jan; 26(1):93-100. PubMed ID: 31562204
[TBL] [Abstract][Full Text] [Related]
5. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
Boichard A; Wagner MJ; Kurzrock R
Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas.
Machado I; Requena C; López-Reig R; Fernández-Serra A; Giner F; Cruz J; Traves V; Lavernia J; Claramunt R; Llombart B; López-Guerrero JA; Llombart-Bosch A
Am J Clin Pathol; 2023 Jul; 160(1):18-34. PubMed ID: 36893014
[TBL] [Abstract][Full Text] [Related]
7. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Murali R; Chandramohan R; Möller I; Scholz SL; Berger M; Huberman K; Viale A; Pirun M; Socci ND; Bouvier N; Bauer S; Artl M; Schilling B; Schimming T; Sucker A; Schwindenhammer B; Grabellus F; Speicher MR; Schaller J; Hillen U; Schadendorf D; Mentzel T; Cheng DT; Wiesner T; Griewank KG
Oncotarget; 2015 Nov; 6(34):36041-52. PubMed ID: 26440310
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating Mast Cells in Angiosarcoma Correlate With Immuno-Oncology Pathways and Adverse Clinical Outcomes.
Tai SB; Lee ECY; Lim BY; Kannan B; Lee JY; Guo Z; Ko TK; Ng CC; Teh BT; Chan JY
Lab Invest; 2024 Mar; 104(3):100323. PubMed ID: 38218317
[TBL] [Abstract][Full Text] [Related]
11.
Xie HM; Bernt KM
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009018
[TBL] [Abstract][Full Text] [Related]
12. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of systemic and local immune responses in human angiosarcoma.
Chan JY; Tan GF; Yeong J; Ong CW; Ng DYX; Lee E; Koh J; Ng CC; Lee JY; Liu W; Wong RX; Ong CJ; Farid M; Teh BT; Soo KC
NPJ Precis Oncol; 2021 Feb; 5(1):11. PubMed ID: 33580206
[TBL] [Abstract][Full Text] [Related]
14. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
[TBL] [Abstract][Full Text] [Related]
15. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
Fanburg-Smith JC; Furlong MA; Childers EL
Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
[TBL] [Abstract][Full Text] [Related]
16. Key roles for MYC, KIT and RET signaling in secondary angiosarcomas.
Styring E; Seinen J; Dominguez-Valentin M; Domanski HA; Jönsson M; von Steyern FV; Hoekstra HJ; Suurmeijer AJ; Nilbert M
Br J Cancer; 2014 Jul; 111(2):407-12. PubMed ID: 24983371
[TBL] [Abstract][Full Text] [Related]
17. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
19. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
20. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
